Every current US GLP-1 label has a paragraph about a missed dose. Ten of them were read for this page on 2026-09-20, and no two state the rule in the same shape.
Some count forward from the dose that was missed. Some count backward from the next one due. Some set a threshold for restarting the escalation and most do not. This page sets them side by side and converts them into one frame, which turns out to reduce a wall of differing numbers to something much smaller.
This is a record of what the labels say. It is not a plan, an instruction or advice, and it does not tell anyone what to do about a dose of their own.
The weekly products, as printed
| Product | Molecule | The provision, in the label's own frame |
|---|---|---|
| OZEMPIC injection | semaglutide | administer "as soon as possible within 5 days after the missed dose"; if more than 5 days have passed, skip and resume |
| WEGOVY injection | semaglutide | if the next scheduled dose is "more than 2 days away", administer as soon as possible; if "less than 2 days away", do not administer |
| ZEPBOUND | tirzepatide | administer "as soon as possible within 4 days (96 hours) after the missed dose"; if more than 4 days have passed, skip and resume |
| MOUNJARO | tirzepatide | word for word the same as ZEPBOUND |
| TRULICITY | dulaglutide | administer "as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose"; if less, skip and resume |
Read down that column and the products look unrelated. Two of them count in days after the miss, two count in days before the next dose, one adds hours in brackets, and the numbers run 5, 2, 4, 4, 3.
The same rules in one frame
A weekly schedule is seven days, so a window stated as d days before the next dose is the same window as one stated as 7 − d days after the missed dose. Converting everything to days-after-the-miss:
| Product | As printed | Converted: catch-up window after the missed dose |
|---|---|---|
| OZEMPIC | within 5 days after | 5 days |
| WEGOVY injection | next dose more than 2 days away | 5 days |
| ZEPBOUND | within 4 days (96 h) after | 4 days |
| MOUNJARO | within 4 days (96 h) after | 4 days |
| TRULICITY | at least 3 days (72 h) until the next dose | 4 days |
Five products, two windows. The two semaglutide injections share one; the two tirzepatide products and dulaglutide share the other. The apparent variety was almost entirely in the wording.
That is worth stating plainly because the most quoted number in this area — WEGOVY's "2 days" — is not a catch-up window at all. It is the distance to the next dose, and a reader who takes it as a window will act on a figure that is wrong by three days.
The daily products: no window at all
| Product | Molecule | The provision |
|---|---|---|
| WEGOVY tablets | semaglutide | "If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day." |
| OZEMPIC tablets / RYBELSUS | semaglutide | "If a dose is missed, skip the missed dose and take the next dose the following day." |
| FOUNDAYO | orforglipron | take the dose "as soon as possible"; "Advise patients not to double up the next dose." |
| VICTOZA | liraglutide | resume "with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose." |
| SAXENDA | liraglutide | resume the once-daily regimen with the next scheduled dose; the same direction against an extra dose |
The daily products have no catch-up arithmetic because there is nothing to catch up to: the next dose is a day away. What they have instead is an explicit direction against doubling, which appears in four of the five.
The reset thresholds, which differ by a factor of seven
A separate question from the catch-up window is how many misses cause the escalation to restart. Only three of the ten labels answer it.
| Product | Reset threshold | What the label directs |
|---|---|---|
| WEGOVY injection | 2 or more consecutive doses | "reinitiate dosage escalation at a lower dosage" |
| VICTOZA | more than 3 days since the last dose | reinitiate at 0.6 mg once daily |
| SAXENDA | more than 3 days since the last dosage | reinitiate at 0.6 mg daily and follow the escalation schedule |
| FOUNDAYO | 7 or more consecutive doses | "reinitiate dosage escalation at a lower dosage" |
| ZEPBOUND, MOUNJARO, TRULICITY, semaglutide tablets | — | no reinitiation provision in the sections read |
WEGOVY resets after two missed weekly doses; FOUNDAYO after seven missed daily ones. In elapsed time those are about fourteen days and about seven, so the products are closer than the raw numbers suggest — but the unit is different and the numbers are stated without it.
Every one of these provisions gives the same reason, and it is the reason the whole class escalates at all: the schedule is reinitiated "to reduce the risk of gastrointestinal adverse reactions." Not to rebuild an effect. To manage tolerance. The full escalation picture is on the titration schedules.
One place where the patient half and the prescriber half differ slightly
SAXENDA's prescriber section directs that after more than 3 days the product be reinitiated at 0.6 mg daily. Its patient-facing Instructions for Use, in the same document, say something softer: if the daily dose is missed "for 3 days or more", call the healthcare provider "to talk about how to restart your treatment."
Same rule, two registers — the clinician's copy gives the dose, the patient's copy gives the phone call. It is a small thing and worth noticing when a figure is quoted from one half of a label as though the whole label said it.
Changing the weekly day
The weekly labels all allow the day of administration to move, and all regulate the gap rather than the day.
| Product | Minimum gap between the two doses |
|---|---|
| OZEMPIC | at least 2 days (more than 48 hours) |
| ZEPBOUND | at least 3 days (72 hours) |
| MOUNJARO | at least 3 days (72 hours) |
| TRULICITY | last dose administered 3 or more days before the new day |
The same two-camp split appears here as in the catch-up windows, and it falls along the same lines.
What this page is not
It is not guidance, and nothing here should be read as telling any reader what to do about a dose. Labels are written for prescribers, the provisions quoted are specific to a named product at a named concentration, and a person who has missed a dose has a prescriber to ask.
There is also no labelled missed-dose rule for a compounded preparation, because there is no approved label for one — see what the compounding statute says. The opposite problem, a dose taken twice or taken too large, is on the overdose page.
Sources
All read 2026-09-20 from each product's current DailyMed SPL:
- OZEMPIC injection (semaglutide), version dated 2026-06-10.
- OZEMPIC tablets and RYBELSUS (oral semaglutide), version dated 2026-08-19.
- WEGOVY injection and tablets (semaglutide), version dated 2026-06-30.
- ZEPBOUND (tirzepatide), version dated 2026-09-02.
- MOUNJARO (tirzepatide), version dated 2026-09-02.
- TRULICITY (dulaglutide), version dated 2026-08-10.
- VICTOZA (liraglutide), version dated 2025-11-17.
- SAXENDA (liraglutide), version dated 2026-06-15.
- FOUNDAYO (orforglipron), version dated 2026-08-13.